Cargando…
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251553/ https://www.ncbi.nlm.nih.gov/pubmed/33661527 http://dx.doi.org/10.1002/ajh.26150 |
| _version_ | 1783717111672078336 |
|---|---|
| author | Korde, Neha Mastey, Donna Tavitian, Elizabet Mailankody, Sham Lesokhin, Alexander Hassoun, Hani Smith, Eric L. Lendvai, Nikoletta Hultcrantz, Malin Shah, Urvi Tan, Carlyn Lu, Sydney Diamond, Benjamin Salcedo, Meghan Werner, Kelly Chung, David J. Scordo, Michael Shah, Gunjan L. Lahoud, Oscar Landau, Heather Arcila, Maria Ho, Caleb Roshal, Mikhail Dogan, Ahmet Derkach, Andriy Devlin, Sean M. Giralt, Sergio A. Landgren, Ola |
| author_facet | Korde, Neha Mastey, Donna Tavitian, Elizabet Mailankody, Sham Lesokhin, Alexander Hassoun, Hani Smith, Eric L. Lendvai, Nikoletta Hultcrantz, Malin Shah, Urvi Tan, Carlyn Lu, Sydney Diamond, Benjamin Salcedo, Meghan Werner, Kelly Chung, David J. Scordo, Michael Shah, Gunjan L. Lahoud, Oscar Landau, Heather Arcila, Maria Ho, Caleb Roshal, Mikhail Dogan, Ahmet Derkach, Andriy Devlin, Sean M. Giralt, Sergio A. Landgren, Ola |
| author_sort | Korde, Neha |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8251553 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley & Sons, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82515532021-07-06 Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone Korde, Neha Mastey, Donna Tavitian, Elizabet Mailankody, Sham Lesokhin, Alexander Hassoun, Hani Smith, Eric L. Lendvai, Nikoletta Hultcrantz, Malin Shah, Urvi Tan, Carlyn Lu, Sydney Diamond, Benjamin Salcedo, Meghan Werner, Kelly Chung, David J. Scordo, Michael Shah, Gunjan L. Lahoud, Oscar Landau, Heather Arcila, Maria Ho, Caleb Roshal, Mikhail Dogan, Ahmet Derkach, Andriy Devlin, Sean M. Giralt, Sergio A. Landgren, Ola Am J Hematol Correspondences John Wiley & Sons, Inc. 2021-03-19 2021-06-01 /pmc/articles/PMC8251553/ /pubmed/33661527 http://dx.doi.org/10.1002/ajh.26150 Text en © 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Correspondences Korde, Neha Mastey, Donna Tavitian, Elizabet Mailankody, Sham Lesokhin, Alexander Hassoun, Hani Smith, Eric L. Lendvai, Nikoletta Hultcrantz, Malin Shah, Urvi Tan, Carlyn Lu, Sydney Diamond, Benjamin Salcedo, Meghan Werner, Kelly Chung, David J. Scordo, Michael Shah, Gunjan L. Lahoud, Oscar Landau, Heather Arcila, Maria Ho, Caleb Roshal, Mikhail Dogan, Ahmet Derkach, Andriy Devlin, Sean M. Giralt, Sergio A. Landgren, Ola Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone |
| title | Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone |
| title_full | Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone |
| title_fullStr | Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone |
| title_full_unstemmed | Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone |
| title_short | Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone |
| title_sort | tailored treatment to mrd response: a phase i/ii study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone |
| topic | Correspondences |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251553/ https://www.ncbi.nlm.nih.gov/pubmed/33661527 http://dx.doi.org/10.1002/ajh.26150 |
| work_keys_str_mv | AT kordeneha tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT masteydonna tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT tavitianelizabet tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT mailankodysham tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT lesokhinalexander tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT hassounhani tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT smithericl tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT lendvainikoletta tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT hultcrantzmalin tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT shahurvi tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT tancarlyn tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT lusydney tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT diamondbenjamin tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT salcedomeghan tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT wernerkelly tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT chungdavidj tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT scordomichael tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT shahgunjanl tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT lahoudoscar tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT landauheather tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT arcilamaria tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT hocaleb tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT roshalmikhail tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT doganahmet tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT derkachandriy tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT devlinseanm tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT giraltsergioa tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone AT landgrenola tailoredtreatmenttomrdresponseaphaseiiistudyfornewlydiagnosedmultiplemyelomapatientsusinghighdosetwiceweeklycarfilzomib45and56mgm2incombinationwithlenalidomideanddexamethasone |